SteelPeak Wealth LLC Buys 1,715 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

SteelPeak Wealth LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 154.8% in the fourth quarter, Holdings Channel reports. The fund owned 2,823 shares of the biopharmaceutical company’s stock after acquiring an additional 1,715 shares during the quarter. SteelPeak Wealth LLC’s holdings in Regeneron Pharmaceuticals were worth $2,011,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Adirondack Trust Co. boosted its stake in Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock valued at $453,000 after purchasing an additional 10 shares during the last quarter. UMB Bank n.a. boosted its position in shares of Regeneron Pharmaceuticals by 1.1% during the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock valued at $955,000 after buying an additional 10 shares during the last quarter. Trust Co. of Vermont grew its holdings in Regeneron Pharmaceuticals by 8.3% during the third quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 12 shares in the last quarter. Nvwm LLC raised its position in Regeneron Pharmaceuticals by 1.4% in the 3rd quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock valued at $1,039,000 after buying an additional 14 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 3.6% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 434 shares of the biopharmaceutical company’s stock valued at $456,000 after acquiring an additional 15 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. BMO Capital Markets lowered their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Oppenheimer dropped their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Evercore ISI reduced their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Sanford C. Bernstein cut their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Finally, Citigroup decreased their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research report on Tuesday. One research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $1,004.57.

Regeneron Pharmaceuticals Stock Up 0.1 %

Shares of NASDAQ REGN opened at $687.27 on Thursday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company has a market cap of $75.52 billion, a P/E ratio of 17.01, a P/E/G ratio of 1.59 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 52 week low of $666.25 and a 52 week high of $1,211.20. The business has a 50-day simple moving average of $724.48 and a two-hundred day simple moving average of $930.31.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.